Regional Veterinary Director Sacramento, CA, United States
After this session, attendees will be able to: (1) Describe the pharmacologic properties of pimobendan; (2) Discuss contexts (specific diseases and disease stages) in which pimobendan has demonstrated clinical benefit in small animals; (3) Identify dogs with stage B2 degenerative mitral valve disease both with and without echocardiographic information; and (4) Weigh benefit vs. risk of pimobendan in clinical scenarios where insufficient evidence exists to recommend its use.
Learning Objectives:
Describe the pharmacologic properties of pimobendan
Discuss contexts (specific diseases and disease stages) in which pimobendan has demonstrated clinical benefit in small animals
Identify dogs with stage B2 degenerative mitral valve disease both with and without echocardiographic information
Weigh benefit vs. risk of pimobendan in clinical scenarios where insufficient evidence exists to recommend its use
